Osteoporosis research center to test drug compound

As part of the effort to find a solution to the impending osteoporosis crisis, the Osteoporosis Clinical Research Center has been chosen as one of only a dozen sites worldwide to conduct a clinical trial involving 2MD, a vitamin D-based drug compound that builds bone mass. 2MD was developed by Deltanoid Pharmaceuticals, a Madison-based startup company under the leadership of Hector DeLuca, chair of the Department of Biochemistry. In May of this year, 2MD was shown to be safe for use in humans; Pfizer purchased the right to develop the drug and begin conducting further trials.

Trial coordinators at the Osteoporosis Clinical Research Center are seeking 30-40 post-menopausal women who aren’t currently taking calcium supplements to participate in the trial. About half the study participants will receive doses of 2MD, while the other half will receive a placebo.

Women interested in participating must have a daily calcium intake (diet and supplements combined) of no more than 1,000 milligrams. The average postmenopausal woman’s calcium intake is 600 mg.

For more information, contact the Osteoporosis Clinical Research Center at 263-2663.